Literature DB >> 21963429

Angiotensin II mediates cell survival through upregulation and activation of the serum and glucocorticoid inducible kinase 1.

Rebekah Baskin1, Peter P Sayeski2.   

Abstract

The serum- and glucocorticoid-inducible kinase 1 (SGK1) is known to regulate a wide variety of cellular processes, including renal sodium retention and cell survival. Angiotensin II (Ang II) is one of the many signaling molecules capable of regulating SGK1 expression, and is also known to impact cell survival. Here, we examined the role of SGK1 in Ang II-mediated cell survival. We hypothesized that Ang II protects cells from apoptosis by upregulating and activating SGK1. To test this, we examined the effects of Ang II stimulation on SGK1 expression and downstream signaling. We also examined the effects of Ang II treatment and siRNA-mediated SGK1 knockdown on apoptosis after serum starvation. We found that after 2h of Ang II treatment, SGK1 mRNA expression was increased approximately 2-fold. This induction was sensitive to reductions in intracellular calcium levels after pretreatment with BAPTA-AM, but insensitive to the L-type calcium channel blocker verapamil. SGK1 induction was also sensitive to the tyrosine kinase inhibitor genistein. Ang II treatment also caused a rapid increase in the level of phosphorylation of SGK1 at Ser422 and Thr256, and Ser422 phosphorylation was rapamycin-sensitive. We found that Ang II treatment was protective against serum starvation-induced apoptosis, and this protective effect was significantly blunted when SGK1 was silenced via siRNA. Lastly, Ang II induced FOXO3A phosphorylation in an SGK1-dependent manner, thereby reducing the pro-apoptotic actions of FOXO3A. Overall, these results indicate that Ang II upregulates and activates SGK1, leading to increased cell survival via multiple, non-redundant mechanisms.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963429      PMCID: PMC3237851          DOI: 10.1016/j.cellsig.2011.09.016

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  26 in total

Review 1.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system.

Authors:  Puja K Mehta; Kathy K Griendling
Journal:  Am J Physiol Cell Physiol       Date:  2006-07-26       Impact factor: 4.249

2.  Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).

Authors:  A Brunet; J Park; H Tran; L S Hu; B A Hemmings; M E Greenberg
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin.

Authors:  Adam Whaley-Connell; Javad Habibi; Zachary Panfili; Melvin R Hayden; Sarika Bagree; Ravi Nistala; Safwan Hyder; Bennett Krueger; Vincent Demarco; Lakshmi Pulakat; Carlos M Ferrario; Alan Parrish; James R Sowers
Journal:  Am J Nephrol       Date:  2011-06-29       Impact factor: 3.754

Review 4.  Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases.

Authors:  Marta Ruiz-Ortega; Mónica Rupérez; Vanesa Esteban; Juan Rodríguez-Vita; Elsa Sánchez-López; Giselle Carvajal; Jesús Egido
Journal:  Nephrol Dial Transplant       Date:  2005-11-09       Impact factor: 5.992

5.  Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2.

Authors:  T Kobayashi; P Cohen
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

6.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

7.  Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase.

Authors:  Liping Zhang; Ruwen Cui; Xiaodong Cheng; Jie Du
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

8.  Jak2 tyrosine kinase mediates angiotensin II-dependent inactivation of ERK2 via induction of mitogen-activated protein kinase phosphatase 1.

Authors:  Eric M Sandberg; Xianyue Ma; Dannielle VonDerLinden; Michael D Godeny; Peter P Sayeski
Journal:  J Biol Chem       Date:  2003-10-09       Impact factor: 5.157

9.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.

Authors:  Estela Jacinto; Robbie Loewith; Anja Schmidt; Shuo Lin; Markus A Rüegg; Alan Hall; Michael N Hall
Journal:  Nat Cell Biol       Date:  2004-10-03       Impact factor: 28.824

10.  Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells.

Authors:  Wei Wu; Shamita Chaudhuri; Deanna R Brickley; Diana Pang; Theodore Karrison; Suzanne D Conzen
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

View more
  9 in total

1.  Phosphorylation at distinct subcellular locations underlies specificity in mTORC2-mediated activation of SGK1 and Akt.

Authors:  Catherine E Gleason; Juan A Oses-Prieto; Kathy H Li; Bidisha Saha; Gavin Situ; Alma L Burlingame; David Pearce
Journal:  J Cell Sci       Date:  2019-04-09       Impact factor: 5.285

Review 2.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

3.  Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.

Authors:  Ben A Hall; Tae Yeon Kim; Maxwell N Skor; Suzanne D Conzen
Journal:  Breast Cancer Res Treat       Date:  2012-07-29       Impact factor: 4.872

4.  20-Hydroxyeicosatetraenoic Acid (HETE)-dependent Hypertension in Human Cytochrome P450 (CYP) 4A11 Transgenic Mice: NORMALIZATION OF BLOOD PRESSURE BY SODIUM RESTRICTION, HYDROCHLOROTHIAZIDE, OR BLOCKADE OF THE TYPE 1 ANGIOTENSIN II RECEPTOR.

Authors:  Üzen Savas; Shouzou Wei; Mei-Hui Hsu; John R Falck; F Peter Guengerich; Jorge H Capdevila; Eric F Johnson
Journal:  J Biol Chem       Date:  2016-06-13       Impact factor: 5.157

5.  A salt-sensing kinase in T lymphocytes, SGK1, drives hypertension and hypertensive end-organ damage.

Authors:  Allison E Norlander; Mohamed A Saleh; Arvind K Pandey; Hana A Itani; Jing Wu; Liang Xiao; Jooeun Kang; Bethany L Dale; Slavina B Goleva; Fanny Laroumanie; Liping Du; David G Harrison; Meena S Madhur
Journal:  JCI Insight       Date:  2017-07-06

6.  Spinal serum-inducible and glucocorticoid-inducible kinase 1 mediates neuropathic pain via kalirin and downstream PSD-95-dependent NR2B phosphorylation in rats.

Authors:  Hsien-Yu Peng; Gin-Den Chen; Cheng-Yuan Lai; Ming-Chun Hsieh; Tzer-Bin Lin
Journal:  J Neurosci       Date:  2013-03-20       Impact factor: 6.167

7.  The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.

Authors:  Rebekah Baskin; Sung O Park; György M Keserű; Kirpal S Bisht; Heather L Wamsley; Peter P Sayeski
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

8.  Targeting serum glucocorticoid-regulated kinase-1 in squamous cell carcinoma of the head and neck: a novel modality of local control.

Authors:  Henrik O Berdel; Hongyu Yin; Jun Yao Liu; Karolina Grochowska; Christopher Middleton; Nathan Yanasak; Rafik Abdelsayed; Wolfgang E Berdel; Mahmood Mozaffari; Jack C Yu; Babak Baban
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

9.  Lack of PPARβ/δ-Inactivated SGK-1 Is Implicated in Liver Carcinogenesis.

Authors:  Bo Shen; Aimin Li; Yu-Jui Yvonne Wan; Guijia Shen; Jinshui Zhu; Yuqiang Nie
Journal:  Biomed Res Int       Date:  2020-10-02       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.